Q-omics provides the consensus-scored GK5 profile across patient tissues and cancer cell-line models. GK5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, GK5 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, GK5 RNA expression shows 20,200 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KIRC, and UVM as cancer lineages where GK5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GK5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GK5 survival associations across molecular data types. GK5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GK5 RNA expression–survival associations across cancer types. High GK5 expression shows unfavorable associations in KICH, LIHC, UVM and ESCA, but favorable associations in BRCA and READ. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify BRCA as the clearest survival context for GK5 RNA expression.
This table summarizes GK5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GK5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GK5 shows lower tumor expression in KIRC and higher tumor expression in LIHC, CHOL, BLCA, ESCA and LUSC. The KIRC box plot shows higher GK5 RNA expression in normal versus tumor tissue (log2 FC = −0.733, t-test p < 0.001).
This table shows molecular features associated with GK5 in patient tissues and cancer cell lines. In patient samples, GK5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GK5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
